S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.